Presence of protein marks toxicity in leukemia
the ONA take:
A recent study examined the protein inositol polyphosphate 4-phosphatase II (INPP4B) in patients that had been diagnosed with acute myeloid leukemia.
When examined, the data indicated that the presence of this protein indicates a likely toxicity effect associated with chemotherapy.
Chemotherapy is a standard clinic treatment for this disease, but patients can now be screened for inositol polyphosphate 4-phosphatase II and recommended for other treatments less likely to be toxic as needed.
The researchers hope to explore exactly how the protein behaves in cancer cells, specifically related to chemoresistance, so the protein and pathway may one day be effectively targeted.
This research was led by PhD student Sewa Rijal from the Faculty of Medicine, Nursing and Health Sciences (FMNHS), under the supervision of Professor Andrew Wei and Professor Christina Mitchell, Dean of FMNHS. Findings were published in the journal Blood.
Presence of this protein indicates a likely toxicity effect associated with chemotherapy.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|